CN111743977A - 一种用于预防和辅助治疗肺炎的中药组合物及其制备方法 - Google Patents
一种用于预防和辅助治疗肺炎的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN111743977A CN111743977A CN202010717895.6A CN202010717895A CN111743977A CN 111743977 A CN111743977 A CN 111743977A CN 202010717895 A CN202010717895 A CN 202010717895A CN 111743977 A CN111743977 A CN 111743977A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- pneumonia
- drying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000003814 drug Substances 0.000 claims abstract description 40
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 28
- 239000012535 impurity Substances 0.000 claims abstract description 28
- 238000000605 extraction Methods 0.000 claims abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000009636 Huang Qi Substances 0.000 claims abstract description 23
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000002594 Solanum nigrum Nutrition 0.000 claims abstract description 21
- 241000222336 Ganoderma Species 0.000 claims abstract description 17
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 16
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 16
- 240000002307 Solanum ptychanthum Species 0.000 claims abstract description 12
- 235000006533 astragalus Nutrition 0.000 claims abstract description 11
- 241001598107 Imperata Species 0.000 claims abstract description 10
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 10
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 9
- 244000061457 Solanum nigrum Species 0.000 claims abstract description 9
- 241001061264 Astragalus Species 0.000 claims abstract description 7
- 210000004233 talus Anatomy 0.000 claims abstract description 7
- 238000009098 adjuvant therapy Methods 0.000 claims abstract description 6
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 5
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 32
- 238000001914 filtration Methods 0.000 claims description 26
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 20
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 20
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 20
- 238000001816 cooling Methods 0.000 claims description 20
- 238000001035 drying Methods 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 17
- 238000004140 cleaning Methods 0.000 claims description 16
- 240000008397 Ganoderma lucidum Species 0.000 claims description 14
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 14
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 13
- 235000011477 liquorice Nutrition 0.000 claims description 13
- 239000000341 volatile oil Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- 239000003957 anion exchange resin Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 241000196324 Embryophyta Species 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000005520 cutting process Methods 0.000 claims description 8
- 238000004042 decolorization Methods 0.000 claims description 8
- 235000012907 honey Nutrition 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 238000003809 water extraction Methods 0.000 claims description 8
- 241000213006 Angelica dahurica Species 0.000 claims description 7
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 7
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 7
- 235000014676 Phragmites communis Nutrition 0.000 claims description 7
- 239000008395 clarifying agent Substances 0.000 claims description 7
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 244000132619 red sage Species 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 244000061520 Angelica archangelica Species 0.000 claims description 4
- 240000007164 Salvia officinalis Species 0.000 claims description 4
- 235000005412 red sage Nutrition 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 240000007171 Imperata cylindrica Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 241000382455 Angelica sinensis Species 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000000284 extract Substances 0.000 abstract description 2
- 239000011347 resin Substances 0.000 abstract description 2
- 229920005989 resin Polymers 0.000 abstract description 2
- 241000712461 unidentified influenza virus Species 0.000 abstract description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 2
- 240000002045 Guettarda speciosa Species 0.000 abstract 1
- 241000207929 Scutellaria Species 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 description 19
- 210000004072 lung Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 230000007812 deficiency Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 10
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 206010007247 Carbuncle Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000003825 pressing Methods 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 206010003549 asthenia Diseases 0.000 description 5
- 229940107666 astragalus root Drugs 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 241000045403 Astragalus propinquus Species 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 208000026425 severe pneumonia Diseases 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 241000675108 Citrus tangerina Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241000212322 Levisticum officinale Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000001645 levisticum officinale Substances 0.000 description 2
- 239000011344 liquid material Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010027783 Moaning Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于预防和辅助治疗肺炎的中药组合物,包括如下重量份的组分:灵芝3~10份、炙黄芪2~18份、黄精5~12份、白芷3~22份、橘红7~20份、金银花4~25份、芦根2~18份、白茅根2~18份、炙甘草2~8份、和/或当归2~18份、川芎2~18份、丹参2~18份、和/或酒炒黄芩3‑15份、龙葵2~30份;本发明的有益效果是利用大孔树脂去除提取物中的杂质,获得纯度较高的药物有效成分;提取溶液大多选取水和乙醇,成本低廉;配方中加入当归、川芎、丹参和黄芪配伍可避免肺炎患者的肺纤维化;龙葵和酒炒黄芩配伍具有良好的抗炎抗病毒作用,抑制人体内流感病毒的活性;本发明对于肺炎的预防和辅助治疗疗效显著,副作用小。
Description
技术领域
本发明属于天然药物技术领域,涉及一种治疗呼吸道疾病的中药组合物,特别是一种用于预防和辅助治疗肺炎的中药组合物。
背景技术
肺炎是指肺泡和肺间质组织的肺实质感染,临床主要症状为发热、咳嗽、咳痰、痰中带血,可伴胸痛或呼吸困难等,并有胸部X线的异常改变。重症患者可累及循环、消化及神经系统而出现相应的临床症状。
对于肺炎的治疗,早期使用适当的抗菌药物可减轻症状及缩短病程,大环内酯类抗菌药物为首选,如红霉素、罗红霉素和阿奇霉素,氟喹诺酮类如左氧氟沙星、加替沙星和莫西沙星等。疗程一般2~3周。使用西药治疗肺炎不仅治疗周期长,且副作用较大,也会产生耐药性及产生肝、肾毒性等不良反应,治标不治本,容易反复发作,还可能影响儿童的发育;
近年来,中药材因其资源丰富,毒副作用小,无耐药性,逐渐得到人们重视,其中,越来越多的治疗呼吸道疾病的中药组合物涌现出来,不仅具有治疗效果,还具有一定的营养保健作用,成为解决西药制剂问题的新途径。
发明内容
本发明的目的是提供一种用于预防和辅助治疗肺炎的中药组合物,要解决如何使预防和辅助治疗肺炎效果显著,毒副作用小的技术问题;以及如何制备该中药组合物。
为实现上述目的,本发明采用如下技术方案:
本发明提供一种用于预防和辅助治疗肺炎的中药组合物,包括以下重量份数计的组分:灵芝3~10份、炙黄芪2~18份、黄精5~12份、白芷3~22份、橘红7~20份、金银花4~25份、芦根2~18份、白茅根2~18份、炙甘草2~8份。
作为优选方案,,还包括以下重量份数计的组成:当归2~18份、川芎2~18份和丹参2~18份。
作为优选方案,还包括以下重量份数计的组成:酒炒黄芩3-15份,龙葵2~30份。
选用灵芝是因为其甘,平。归心、肺、肝、肾经;补气安神,止咳平喘;补气安神,止咳平喘。用于心神不宁,失眠心悸,肺虚咳喘,虚劳短气,不思饮,具有提高免疫力和抵抗力的功效。
选用黄芪是因为其性味甘、温。归肺、脾经;补气固表,利尿托毒,排脓,敛疮生肌。用于气虚乏力,食少便溏,中气下陷,表虚自汗,气虚水肿,痈疽难溃,久溃不敛,血虚痿黄,内热消渴;选用炙黄芪是因为其益气补中。用于气虚乏力,食少便溏。
选用黄精是因为其甘、平,归脾、肺、肾经;补气养阴,健脾,润肺,益肾。用于脾胃气虚,体倦乏力,胃阴不足,口干食少,肺虚燥咳,劳嗽咳血,精血不足,腰膝酸软,须发早白,内热消渴。
选用白芷是因为其辛,温。归胃、大肠、肺经;养血调经,敛阴止汗,柔肝止痛,平抑肝阳。用于血虚萎黄,月经不调,自汗,盗汗,胁痛,腹痛,四肢挛痛,头痛眩晕。
选用橘红是因为其苦,平。归肝、肾经;理气宽中,燥湿化痰。用于咳嗽痰多,食积伤酒,呕恶痞闷。
选用金银花是因为其性味甘,寒,入肺、胃经,有清热,解毒的功能,治温病发热,热毒血痢,痈疡,肿毒,瘰疬,痔漏。
选用芦根是因为其甘,寒。归肺、胃经;清热泻火,生津止渴,除烦,止呕,利尿。用于热病烦渴,肺热咳嗽,肺痈吐脓,胃热呕哕,热淋涩痛
选用白茅根是因为其甘,寒。归肺、胄、膀胱经;凉血止血,清热利尿。用于血热吐血,衄血,尿血,热病烦渴,湿热黄疸,水肿尿少,热淋涩痛。
选用甘草是因为其性味甘,平,入脾、胃、肺经,有和中缓急,润肺,解毒,调和诸药的功能;炙用,治脾胃食少,腹痛便溏,劳倦发热,肺痿咳嗽,心悸,惊癎;生用,治咽喉肿痛,消化性溃疡,痈疸疮疡,解药毒及食物中毒。
选用当归是因为其性味甘辛,温,入心、肝、脾经,有补血和血,调经止痛,润燥滑肠的功能,治月经不调,经闭腹痛,癥瘕结聚,崩漏,血虚头痛,眩晕,痿痹,肠燥难便,赤痢后重,痈疽疮疡,金疮,跌扑损伤。
选用川芎是因为其性味辛、温。归肝、胆、心包经。善活血行气,祛风止痛。《日华子本草》载:“治一切风,一切气,一切劳损,一切血,补五劳,壮筋骨,调众脉,破症结宿血……”。
选用丹参是因为其苦,微寒。归心、肝经活血祛瘀,通经止痛,清心除烦,凉血消痈。
选用龙葵是因为其味苦,性寒。清热消炎,凉血解毒,软坚消肿。
选用黄芩是因为其苦,寒;归肺、胆、脾、大肠、小肠经;清热燥湿,泻火解毒,止血,安胎。用于湿温、暑湿,胸闷呕恶,湿热痞满,泻痢,黄疸,肺热咳嗽,高热烦渴,血热吐衄,痈肿疮毒,胎动不安。
另外,本发明还提供了一种用于预防和辅助治疗肺炎的中药组合物的制备方法,具体步骤如下。
(一)备料
灵芝:灵芝全草挑拣、清洗、除杂、切碎;
炙黄芪:取黄芪片加炼蜜与开水少许,拌匀,稍闷,置锅内用文火炒至变为深黄色,不粘手为止,取出放凉,黄芪和炼蜜的重量比为4:1;
黄精:除去杂质,洗净,略润,切厚片,干燥;
白芷:除去杂质,大小分开,略浸,润透,切厚片,干燥;
橘红:除去杂质,切碎;
金银花:筛去泥沙,拣净杂质;
芦根:去杂质,洗净,切段,干燥;
白茅根:洗净,微润,切段,干燥,除去碎屑;
炙甘草:取甘草片加炼蜜与开水少许,拌匀,稍闷,置锅内用文火炒至变为深黄色,不粘手为止,取出放凉,甘草和炼蜜的重量比为4:1;
当归:拣去杂质,洗净,闷润,稍晾至内外湿度适宜时,切片晒干;
川芎:除去杂质,分开大小,洗净,润透,切厚片,干燥;
丹参:除去杂质和残茎,洗净,润透,切厚片,干燥;
龙葵:取成熟龙葵紫色的果干,洗净;
酒炒黄芩:黄芩用酒拌湿炒;
(二)制备
a、当归、川芎常规提取挥发油,收集馏液和蒸馏水,备用;
b、灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草、丹参、酒炒黄芩、龙葵的提取步骤:
b1、将a工序的药渣与灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草加水后水提取三次,每次用水量为原料总质量的8~10倍,每次水提温度控制在80~95℃,,每次提取时间为2~3h,合并三次提取液,过滤分离出滤液和滤渣;
b2、将b1步骤的滤液浓缩至固含量为0.1~0.2g/ml的浓缩液,冷却、静置至室温;
b3、将b2步骤的浓缩液加入6%~10%的植物提取澄清剂除去提取液杂质及大分子不稳定成分,过滤得到澄清液;
b4、将b3步骤的澄清液加入大孔弱碱性苯乙烯阴离子交换树脂进行脱色处理,在水浴条件下脱色5~7h,过滤得到脱色后的澄清液;
c、将b工序的提取液与a工序的蒸馏水合并,浓缩后加入乙醇,调节浓缩液的乙醇含量至40~80%,静置7~50小时,滤过并回收乙醇,再加入a工序的馏液,于0~10℃下冷藏9~40小时,滤过,滤液备用;
作为优选方案,所述b4步骤的澄清液杀菌冷却后,喷雾干燥即得固体粉末,再加工成口服剂,封装。
作为优选方案,将所述a工序的挥发油用2~7倍量乙醇溶解后加入b工序的澄清液中,然后加工制成口服剂,封装。
最终药液的乙醇含量为40~80%。
作为优选方案,所述大孔弱碱性苯乙烯阴离子交换树脂为D303型。
作为优选方案,所述的口服剂是合剂或者散剂或者片剂或者胶囊剂或者颗粒剂或者丸剂。
作为优选方案,所述的中药组合物用于制作食品、保健品或药品。
与现有技术相比,本发明具有如下的有益效果:
1,本发明选用植物澄清剂和大孔树脂去除提取物中的杂质,从而得到澄清透明的药液,以及纯度较高的药物有效成分;本方法与传统熬煮工艺相比减少了能耗,降低了生产成本,减少对环境的污染,工艺易于推广。
2,本发明选用炙黄芪和炙甘草可以使这两味药更加温和,更有利于缓和药性,消除药的副作用。
3,本发明将芦根和白茅根配伍使用,增强对肺热咳喘等的疗效。
4,本发明选用当归、川芎、丹参和黄芪,使这几味药协同作用从而避免肺炎患者的肺纤维化;对物理刺激和化学刺激所致咳嗽均有一定的抑制作用,可以舒张气管平滑肌,对抗乙酰胆碱和组胺所致的气管平滑肌收缩,对组织胺引起的支气管痉挛有一定的缓解作用。
5,本发明选用的龙葵和酒炒黄芩具有良好的抗炎抗菌效果,不仅可以抑制人体内流感病毒的活性,又起到消肿散结、止咳祛痰的作用,与其他几味药共同作用,逐步缓解患者的肺炎症状,可以显著改善肺炎患者的临床表征。
6,本发明选用酒黄芩,其对人体的免疫系统具有明显的影响,其含有黄芩苷可以提高人体内巨噬细胞的活性,可减少有害物质对人体免疫细胞的伤害,也能增加免疫球蛋白的数量,与灵芝共同作用提高人体自身免疫功能,帮助病患通过自身免疫逐步缓解肺炎的临床表征。
7,提取溶液大多选取水和乙醇,成本低廉。
本发明的其它特征和优点将在随后的说明书中阐述,并且部分地从说明书中变得显而易见,或者通过实施本发明而了解。本发明的主要目的和其它优点可通过在说明书中所特别指出的方案来实现和获得。
具体实施方式
下面结合具体实施例对本发明进行详细说明。以下实施例将有助于本领域的技术人员进一步理解本发明,但不以任何形式限制本发明。应当指出的是,对本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进。这些都属于本发明的保护范围。
实施例1
本实施例涉及一种用于预防和辅助治疗肺炎的中药组合物,由按重量份数计的如下组分组成:灵芝3份、炙黄芪2份、黄精5份、白芷3份、橘红7份、金银花4份、芦根2份、白茅根2份、炙甘草2份。
a、灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草的提取步骤:
a1、灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草加水后水提取三次,每次用水量为原料总质量的8倍,每次水提温度控制在85℃,每次提取时间为2h,合并三次提取液,过滤分离出滤液和滤渣;
a2、将a1步骤的滤液浓缩至固含量为0.2g/ml的浓缩液,冷却、静置至室温;
a3、将a2步骤的浓缩液加入6%的植物提取澄清剂除去提取液杂质及大分子不稳定成分,过滤得到澄清液;
a4、将a3步骤的澄清液加入大孔弱碱性苯乙烯阴离子交换树脂进行脱色处理,在水浴条件下脱色5h,过滤得到脱色后的澄清液;
b、将a4步骤的澄清液杀菌冷却后,喷雾干燥即得固体粉末,与碳酸氢钠、酒石酸、填充剂、粘合剂、润滑剂、甜味剂混合均匀后,压制成泡腾片。
实施例2
本实施例涉及一种用于预防和辅助治疗肺炎的中药组合物,由按重量份数计的如下组分组成:灵芝10份、炙黄芪18份、黄精12份、白芷22份、橘红20份、金银花25份、芦根18份、白茅根18份、炙甘草8份。
a、灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草的提取步骤:
a1、灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草加水后水提取三次,每次用水量为原料总质量的10倍,每次水提温度控制在90℃,,每次提取时间为3h,合并三次提取液,过滤分离出滤液和滤渣;
a2、将a1步骤的滤液浓缩至固含量为0.2g/ml的浓缩液,冷却、静置至室温;
a3、将a2步骤的浓缩液加入8%的植物提取澄清剂除去提取液杂质及大分子不稳定成分,过滤得到澄清液;
a4、将a3步骤的澄清液加入大孔弱碱性苯乙烯阴离子交换树脂进行脱色处理,在水浴条件下脱色5h,过滤得到脱色后的澄清液;
b、将a4步骤的澄清液杀菌冷却后,喷雾干燥即得固体粉末,与适量大豆油、蜂蜡搅拌混匀后,用胶体磨将料液研磨至均匀、细腻、无颗粒的状态;
C、配制明胶、甘油和水的混合物,压制软胶囊皮,加入二氧化钛作为遮光剂,加入焦糖色素改变外观色泽,将b步骤所得料液作为内容物压制成软胶囊,室温下冷却2h,干燥后封装。
实施例3
本实施例涉及一种用于预防和辅助治疗肺炎的中药组合物,由按重量份数计的如下组分组成:灵芝6份、炙黄芪12份、黄精7份、白芷15份、橘红13份、金银花18份、芦根13份、白茅根13份、炙甘草5份。
a、灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草的提取步骤:
a1、灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草加水后水提取三次,每次用水量为原料总质量的10倍,每次水提温度控制在95℃,,每次提取时间为3h,合并三次提取液,过滤分离出滤液和滤渣;
a2、将a1步骤的滤液浓缩至固含量为0.1g/ml的浓缩液,冷却、静置至室温;
a3、将a2步骤的浓缩液加入10%的植物提取澄清剂除去提取液杂质及大分子不稳定成分,过滤得到澄清液;
a4、将a3步骤的澄清液加入大孔弱碱性苯乙烯阴离子交换树脂进行脱色处理,在水浴条件下脱色7h,过滤得到脱色后的澄清液;
b、将a4步骤的澄清液杀菌冷却后,加工成口服剂,封装。
实施例4
本实施例涉及一种用于预防和辅助治疗肺炎的中药组合物,由按重量份数计的如下组分组成:灵芝3份、炙黄芪2份、黄精5份、白芷3份、橘红7份、金银花4份、芦根2份、白茅根2份、炙甘草2份、当归2份、川芎2份、丹参2份、龙葵2份和酒炒黄芩3份。
a、当归、川芎常规提取挥发油,收集馏液和蒸馏水,备用;
b、灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草、丹参、酒炒黄芩、龙葵的提取步骤:
b1、将a工序的药渣与灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草加水后水提取三次,每次用水量为原料总质量的8倍,每次水提温度控制在85℃,,每次提取时间为2h,合并三次提取液,过滤分离出滤液和滤渣;
b2、将b1步骤的滤液浓缩至固含量为0.2g/ml的浓缩液,冷却、静置至室温;
b3、将b2步骤的浓缩液加入6%的植物提取澄清剂除去提取液杂质及大分子不稳定成分,过滤得到澄清液;
b4、将b3步骤的澄清液加入大孔弱碱性苯乙烯阴离子交换树脂进行脱色处理,在水浴条件下脱色5h,过滤得到脱色后的澄清液;
b5、将所述a工序的挥发油用2~7倍量乙醇溶解后加入b4工序的澄清液中,备用。
c、将b5步骤的澄清液杀菌冷却后,喷雾干燥即得固体粉末,与碳酸氢钠、酒石酸、填充剂、粘合剂、润滑剂、甜味剂混合均匀后,压制成泡腾片。
实施例5
本实施例涉及一种用于预防和辅助治疗肺炎的中药组合物,由按重量份数计的如下组分组成:灵芝10份、炙黄芪18份、黄精12份、白芷22份、橘红20份、金银花25份、芦根18份、白茅根18份、炙甘草8份、当归18份、川芎18份、丹参18份、龙葵30份和酒炒黄芩15份。
a、当归、川芎常规提取挥发油,收集馏液和蒸馏水,备用;
b、灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草、丹参、酒炒黄芩、龙葵的提取步骤:
b1、将a工序的药渣与灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草加水后水提取三次,每次用水量为原料总质量的10倍,每次水提温度控制在95℃,,每次提取时间为3h,合并三次提取液,过滤分离出滤液和滤渣;
b2、将b1步骤的滤液浓缩至固含量为0.15g/ml的浓缩液,冷却、静置至室温;
b3、将b2步骤的浓缩液加入8%的植物提取澄清剂除去提取液杂质及大分子不稳定成分,过滤得到澄清液;
b4、将b3步骤的澄清液加入大孔弱碱性苯乙烯阴离子交换树脂进行脱色处理,在水浴条件下脱色6h,过滤得到脱色后的澄清液;
b5、将所述a工序的挥发油用2~7倍量乙醇溶解后加入b4工序的澄清液中,备用。
c、将b5步骤的澄清液杀菌冷却后,喷雾干燥即得固体粉末,与适量大豆油、蜂蜡搅拌混匀后,用胶体磨将料液研磨至均匀、细腻、无颗粒的状态;
d、配制明胶、甘油和水的混合物,压制软胶囊皮,加入二氧化钛作为遮光剂,加入焦糖色素改变外观色泽,将c步骤所得料液作为内容物压制成软胶囊,室温下冷却2h,干燥后封装。
实施例6
本实施例涉及一种用于预防和辅助治疗肺炎的中药组合物,由按重量份数计的如下组分组成:灵芝4份、炙黄芪7份、黄精8份、白芷12份、橘红16份、金银花20份、芦根15份、白茅根15份、炙甘草5份、当归13份、川芎13份、丹参16份、龙葵17份和酒炒黄芩10份。
a、当归、川芎常规提取挥发油,收集馏液和蒸馏水,备用;
b、灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草、丹参、酒炒黄芩、龙葵的提取步骤:
b1、将a工序的药渣与灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草加水后水提取三次,每次用水量为原料总质量的9倍,每次水提温度控制在95℃,,每次提取时间为2.5h,合并三次提取液,过滤分离出滤液和滤渣;
b2、将b1步骤的滤液浓缩至固含量为0.15g/ml的浓缩液,冷却、静置至室温;
b3、将b2步骤的浓缩液加入10%的植物提取澄清剂除去提取液杂质及大分子不稳定成分,过滤得到澄清液;
b4、将b3步骤的澄清液加入大孔弱碱性苯乙烯阴离子交换树脂进行脱色处理,在水浴条件下脱色7h,过滤得到脱色后的澄清液;
b5、将所述a工序的挥发油用2~7倍量乙醇溶解后加入b4工序的澄清液中,备用。
c、将b步骤的澄清液杀菌冷却后,加工成口服剂,封装。
结合生物试验数据对实施例1~6的效果进行检验:
试验例一:本发明的动物毒性试验报告:
取成年小白鼠30只,雌雄兼用,体重150~200g,分2组,每组15只,因实施例5中包含了本申请的所有中药组合物,并且每种中药重量份数均为最大值,因此选用实施例5进行动物毒性试验。
将实施例5作为超剂量试验组,一组正常量试验组。超常量组为2ml/g,正常量为1ml/g,给药方式为灌胃法给药,每天两次,连续服用7天,每天观察给药反应,结果表明二组小白鼠活动、饮食正常,药物无不良毒副作用。
试验例二:本发明药物的临床观察资料:
1、患者情况:2018年12月~2019年10月收治患者213例,其中轻型150例,重型类63例;年龄在1岁到70岁之间。
2、诊断标准:
轻型类肺炎:开始为频繁的剌激性干咳,咽喉部伴有痰鸣音,咳嗽时可伴有呕吐、呛奶。呼吸表浅增快,患儿伴有精神萎靡,烦躁不安,食欲不振,哆嗦,腹泻等全身症状。
重型类肺炎:呼吸表浅、急促、鼻翼扇动,呼气呻吟,颜面部及四肢末端明显紫绀,甚者面色苍白或青灰,肺部CT有明显阴影等症状。
3、治疗方法:
选用上述药剂,给小儿患者服用,5岁以上每天2剂,每剂分2次服;1~5岁每天1剂,每剂分4次服用。
7天为一疗程,轻型类肺炎根据患者情况服用实施例1~3中的一种连续服用两个疗程;重型类肺炎根据治疗情况及患者情况服用实施例5~6的一种,总共四个疗程。
4、疗效评定标准:
显效:治疗后临床症状消失,体质恢复正常,观察半年无复发者,并且重型肺炎患者CT未显示出现肺纤维化;
好转:临床症状明显改善,体质逐步恢复;
无效:临床部分症状消失或无改变,未见好转者。
5、治疗结果:根据病人的情况服用本发明的实施例1~9后,试验结果如表1。
表1本发明药物的临床观察结果
由表1可以看出,实施例1~3的药物配方适用于轻型肺炎患者,患者一共150人,显效120人,好转28人,另外有2名患者在服药后没有明显改善,有效率达到98.67%;实施例4~6的药物配方在实施例1~3的基础上添加了龙葵和酒炒黄芩,提高了药物的抗炎效果,更有利于重型肺炎患者的治疗,患者共63人,显效25人,好转35人,无效3人,有效率达到95.24%。
由此可见,本发明将芦根和白茅根配伍使用,增强对肺热咳喘等的疗效;实施例4~6是在实施例1~3的基础上增加当归、川芎、丹参、龙葵和酒炒黄芩这五味药,从而避免肺炎患者的肺纤维化;对物理刺激和化学刺激所致咳嗽均有一定的抑制作用,可以舒张气管平滑肌,对抗乙酰胆碱和组胺所致的气管平滑肌收缩,对组织胺引起的支气管痉挛有一定的缓解作用;龙葵和酒炒黄芩具有良好的抗炎效果,起到消肿散结、止咳祛痰的作用,与其他几味药共同作用,逐步缓解患者的肺炎症状,可以显著改善肺炎患者的临床表征。
综上所述,仅为本发明的较佳实施例而已,并非用来限定本发明实施的范围,凡依本发明权利要求范围所述的形状、构造、特征及精神所为的均等变化与修饰,均应包括于本发明的权利要求范围内。
Claims (9)
1.一种用于预防和辅助治疗肺炎的中药组合物,其特征在于,包括以下重量份数计的组分:灵芝3~10份、炙黄芪2~18份、黄精5~12份、白芷3~22份、橘红7~20份、金银花4~25份、芦根2~18份、白茅根2~18份、炙甘草2~8份。
2.如权利要求1所述的一种用于预防和辅助治疗肺炎的中药组合物,其特征在于,还包括以下重量份数计的组成:当归2~18份、川芎2~18份和丹参2~18份。
3.如权利要求2所述的一种用于预防和辅助治疗肺炎的中药组合物,其特征在于,还包括以下重量份数计的组成:酒炒黄芩3-15份,龙葵2~30份。
4.如权利要求1~3任意一项所述的中药组合物的制备方法,其特征在于,包括下列步骤:
(一)备料
灵芝:灵芝全草挑拣、清洗、除杂、切碎;
炙黄芪:取黄芪片加炼蜜与开水少许,拌匀,稍闷,置锅内用文火炒至变为深黄色,不粘手为止,取出放凉,黄芪和炼蜜的重量比为4:1;
黄精:除去杂质,洗净,略润,切厚片,干燥;
白芷:除去杂质,大小分开,略浸,润透,切厚片,干燥;
橘红:除去杂质,切碎;
金银花:筛去泥沙,拣净杂质;
芦根:去杂质,洗净,切段,干燥;
白茅根:洗净,微润,切段,干燥,除去碎屑;
炙甘草:取甘草片加炼蜜与开水少许,拌匀,稍闷,置锅内用文火炒至变为深黄色,不粘手为止,取出放凉,甘草和炼蜜的重量比为4:1;
当归:拣去杂质,洗净,闷润,稍晾至内外湿度适宜时,切片晒干;
川芎:除去杂质,分开大小,洗净,润透,切厚片,干燥;
丹参:除去杂质和残茎,洗净,润透,切厚片,干燥;
龙葵:取成熟龙葵紫色的果干,洗净;
酒炒黄芩:黄芩用酒拌湿炒;
(二)制备
a、当归、川芎常规提取挥发油,收集馏液和蒸馏水,备用;
b、灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草、丹参、酒炒黄芩、龙葵的提取步骤:
b1、将a工序的药渣与灵芝、炙黄芪、黄精、白芷、橘红、金银花、芦根、白茅根、炙甘草加水后水提取三次,每次用水量为原料总质量的8~10倍,每次水提温度控制在80~95℃,,每次提取时间为2~3h,合并三次提取液,过滤分离出滤液和滤渣;
b2、将b1步骤的滤液浓缩至固含量为0.1~0.2g/ml的浓缩液,冷却、静置至室温;
b3、将b2步骤的浓缩液加入6%~10%的植物提取澄清剂除去提取液杂质及大分子不稳定成分,过滤得到澄清液;
b4、将b3步骤的澄清液加入大孔弱碱性苯乙烯阴离子交换树脂进行脱色处理,在水浴条件下脱色5~7h,过滤得到脱色后的澄清液。
5.如权利要求4所述的中药组合物的制备方法,其特征在于,所述b4步骤的澄清液杀菌冷却后,喷雾干燥即得固体粉末,再加工成口服剂,封装。
6.如权利要求4所述的中药组合物的制备方法,其特征在于,将所述a工序的挥发油用2~7倍量乙醇溶解后加入b工序的澄清液中,然后加工制成口服剂,封装。
7.如权利要求4所述的中药组合物的制备方法,其特征在于,所述大孔弱碱性苯乙烯阴离子交换树脂为D303型。
8.如权利要求5或6所述的中药组合物的制备方法,其特征在于,所述的口服剂是合剂或者散剂或者片剂或者胶囊剂或者颗粒剂或者丸剂。
9.如权利要求1~3中任一项所述的一种用于预防和辅助治疗肺炎的中药组合物的应用,其特征在于,所述的中药组合物用于制作食品、保健品或药品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010717895.6A CN111743977A (zh) | 2020-07-23 | 2020-07-23 | 一种用于预防和辅助治疗肺炎的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010717895.6A CN111743977A (zh) | 2020-07-23 | 2020-07-23 | 一种用于预防和辅助治疗肺炎的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111743977A true CN111743977A (zh) | 2020-10-09 |
Family
ID=72710727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010717895.6A Pending CN111743977A (zh) | 2020-07-23 | 2020-07-23 | 一种用于预防和辅助治疗肺炎的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111743977A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1742939A (zh) * | 2005-09-29 | 2006-03-08 | 济南宏济堂制药有限责任公司 | 一种治疗肺间质纤维化的药物及其制备方法 |
CN104758711A (zh) * | 2015-04-30 | 2015-07-08 | 张玮玮 | 一种治疗肺结节病的中药制剂及其制备方法 |
-
2020
- 2020-07-23 CN CN202010717895.6A patent/CN111743977A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1742939A (zh) * | 2005-09-29 | 2006-03-08 | 济南宏济堂制药有限责任公司 | 一种治疗肺间质纤维化的药物及其制备方法 |
CN104758711A (zh) * | 2015-04-30 | 2015-07-08 | 张玮玮 | 一种治疗肺结节病的中药制剂及其制备方法 |
Non-Patent Citations (1)
Title |
---|
李良梅: "益肺通络汤治疗特发性肺间质纤维化40例", 《中国民间疗法》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103860941A (zh) | 一种治疗精神分裂症的中药及其制备方法 | |
CN111298021A (zh) | 一种治疗功能性便秘的中药组合物 | |
CN106109521A (zh) | 一种三七口服液 | |
CN102847061A (zh) | 一种治疗小儿病毒性心肌炎的中药制剂及其制备方法 | |
CN104524174A (zh) | 一种治疗风湿痹痛的中药组合物及其制备方法 | |
CN105148220A (zh) | 一种治疗脾肾阳虚型眩晕的中药及制备方法 | |
CN104547598A (zh) | 一种治疗神经衰弱的中药制剂及制备方法 | |
CN103007145B (zh) | 一种治疗小儿轮状病毒肠炎的中药组合物及其制备方法 | |
CN111743977A (zh) | 一种用于预防和辅助治疗肺炎的中药组合物及其制备方法 | |
CN107648335B (zh) | 调节动脉粥样硬化自噬与凋亡的中药组合物及制备方法 | |
CN105267711A (zh) | 一种用于治疗眩晕症的药物制剂 | |
CN105343660A (zh) | 一种治疗周围性眩晕的中药制剂及其制造方法 | |
CN104623615A (zh) | 一种治疗哮喘的药物 | |
CN104887950A (zh) | 一种治疗乳痈的中药组合物 | |
CN104800600A (zh) | 一种治疗高血压的药物 | |
CN104353043A (zh) | 一种治疗五更泻的中药组合物及其制备方法 | |
CN107951951B (zh) | 一种祛老年斑的中药组合物及其制备方法 | |
CN108404068B (zh) | 一种治疗和/或预防腹泻的药物组合物及其制备方法 | |
CN106177389B (zh) | 具有润肠通便、改善睡眠、增强免疫力功能的中药制剂及其制备方法 | |
CN104784558A (zh) | 一种治疗复发性口腔溃疡的中药组合物及其制备方法 | |
CN105709176A (zh) | 一种治疗心血瘀阻型心悸的中药组合物及其制备方法 | |
CN105456933A (zh) | 一种活血化瘀、通经活络的中药及其制备方法 | |
CN105079425A (zh) | 一种治疗小儿手足口病的组合物制剂及其制备方法 | |
CN104706942A (zh) | 一种治疗脑心综合征的药物组合物及其制备方法 | |
CN115708854A (zh) | 一种治疗皮肤病的三桑消风合剂的中药组合物及其合剂的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201009 |